12:10 PM EST, 11/10/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) said Monday that it has expanded its MyRisk Hereditary Cancer Test with the addition of actionable genes referenced in NCCN Clinical Practice Guidelines in Oncology and guidelines from American Society of Clinical Oncology.

The company said its cancer test now includes 63 genes across more than 11 cancer types.

Shares of Myriad Genetics ( MYGN ) were up more than 2% in recent Monday trading.

Price: 6.46, Change: +0.16, Percent Change: +2.46